- Active not recruitingPHASE1
A CR-UK Phase I Trial of LY3143921
This study is testing a new drug, LY3143921 hydrate, for advanced solid cancers. It aims to find a safe dose, understand side effects, and see how well it works. This drug targets a specific process in cancer cells to stop their growth.
For: A. Colorectal Cancer · B. High Grade Serous Ovarian Cancer · C. Non Small-cell Lung Cancer (squamous Cell Variant)United Kingdom - CompletedPhase I
A Phase I trial of LY3143921 hydrate in solid tumours
This study looks at a new drug, LY3143921 hydrate, for advanced solid cancers. It aims to find a safe dose and understand its effects, especially in cancers where usual treatments haven't worked or aren't suitable. This is the first time it’s being tested in people.
For: Colorectal Cancer (CRC), High Grade Serous Ovarian Cancer (HGSOC), Non-Small Cell Lung Cancer (NSCLC; Squamous Cell Variant), Squamous Carcinoma of the Oesophagus, Squamous Carcinoma of the Head and Neck (Human Papillomavirus Negative), Urothelial Cancer, Breast Cancer (Triple Negative Type), Pancreatic CancerUnited Kingdom · England · Northern Ireland